Determination of Receptor Binding Affinity of Growth Hormone Analogues to the Growth Hormone Receptor in a Drug Screening Context
Simon Erlendsson1; Alina Kulakova1; Svend Poulsen1; Peter Thygesen1
Poster
Publication
Somapacitan Administered Subcutaneously at 5 mg/1.5 mL or 10 mg/1.5 mL Strengths Yields Clinically Similar PK and IGF-I Profiles in Healthy Participants
Michael Højby Rasmussen1; Rasmus Juul Kildemoes1; Claus Sværke1
Poster
Publication
Model-Based Analysis of IGF-I Response, Dosing, and Monitoring for Once-Weekly Somapacitan in Children with GH Deficiency
Rasmus Juul Kildemoes1; Yassine Kamal Lyauk1; Joanne C. Blair2; Bradley S. Miller3; Jun Mori4; Michael Højby Rasmussen1; Philippe F. Backeljauw5
Poster
Publication
Coverage of Education and Training of Traumatic Brain Injury-Induced Growth Hormone Deficiency in US Endocrinology Fellowship Programs
Kevin Choong Ji Yuen1; Radhika Adiga2; Nicky Kelepouris3; Javier Cardenas4
Slide
Saturday, 17 June 2023
Publication
Effective GH Replacement With Once-Weekly Somapacitan in Children With GH Deficiency: 2-Year Results From REAL4
Bradley S. Miller1; Joanne C. Blair2; Michael Højby Rasmussen3; Aristides Maniatis4; Jun Mori5; Volker Böttcher6; Ho-Seong Kim7; Rikke Beck Bang8; Michel Polak9; Reiko Horikawa10
Poster
Publication
Patient Preference Questionnaire Response After Switching to Somapacitan After Taking Daily GH: 2-Year Results From REAL4
Joanne C. Blair1; Bradley S. Miller2; Michael Højby Rasmussen3; Aristides Maniatis4; Jun Mori5; Volker Böttcher6; Ho-Seong Kim7; Rikke Beck Bang8; Lasse De Fries Jensen9; Michel Polak9; Reiko Horikawa10
Poster
Publication
Pre-Treatment Blood Transcriptome Predicts First-year Growth and IGF-I Response to Somapacitan Treatment in Children with GH Deficiency
Terence Garner1; Peter Clayton1,2; Michael Højby3; Philip Murray1,2; Adam Stevens1